NCT06007586 2025-12-04
Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
Sichuan Cancer Hospital and Research Institute
Phase 3 Completed
Clinical Trials
11 trialsNCT03808805 2025-12-03
APHYPAP
University Hospital, Brest
Phase 3 Completed
NCT02116530 2025-01-28
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02939287 2024-10-22
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
Rush University Medical Center
Phase 3 Completed
NCT03674294 2023-02-08
CINV
Sun Yat-sen University
Phase 3 Completed
NCT02336750 2022-04-20
Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis
Fudan University
Phase 3 Completed
NCT01661335 2021-03-23
Efficacy of Aprepitant (Emend®) in Children
University of Oklahoma
Phase 3 Completed
NCT02161991 2020-03-26
Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers
Hunan Province Tumor Hospital
Phase 3 Completed
NCT00092196 2017-05-05
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00572572 2016-04-06
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Hoosier Cancer Research Network
Phase 3 Completed
NCT00475085 2015-11-10
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
University of Rochester
Phase 3 Completed